These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 37427705)
41. Prevalence of bleeding manifestations in 128 heterozygotes for Factor X deficiency, mainly for FX Friuli, matched versus 128 unaffected family members, during a long sequential observation period (23.5 years). Girolami A; Cosi E; Santarossa C; Ferrari S; Girolami B; Lombardi AM Eur J Haematol; 2016 Dec; 97(6):547-553. PubMed ID: 27124643 [TBL] [Abstract][Full Text] [Related]
42. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Boggio L; Green D Br J Haematol; 2001 Mar; 112(4):1074-5. PubMed ID: 11298609 [TBL] [Abstract][Full Text] [Related]
43. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]. Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115 [TBL] [Abstract][Full Text] [Related]
44. Rare post-operative complications in a previously undiagnosed Congenital Factor X deficiency patient. Mohd Nazri H; Suhair AA; Wan Suriana WA; Zefarina Z; Azlan H; Wan Zaidah A Malays J Pathol; 2016 Dec; 38(3):327-331. PubMed ID: 28028305 [TBL] [Abstract][Full Text] [Related]
45. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency. Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408 [TBL] [Abstract][Full Text] [Related]
47. Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study. Öner AF; Celkan T; Timur Ç; Norton M; Kavaklı K Turk J Haematol; 2018 May; 35(2):129-133. PubMed ID: 29545231 [TBL] [Abstract][Full Text] [Related]
48. A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency. Payne J; Batsuli G; Leavitt AD; Mathias M; McGuinn CE Haemophilia; 2022 Jul; 28(4):523-531. PubMed ID: 35499465 [TBL] [Abstract][Full Text] [Related]
49. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy. Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649 [TBL] [Abstract][Full Text] [Related]
50. [Primary light chain amyloidosis onset with acquired FX deficiency: a case report and literature review]. Wei C; Feng J; Zhu TN Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):680-682. PubMed ID: 32942824 [No Abstract] [Full Text] [Related]
51. Normalization of plasma factor X levels in amyloidosis after plasma exchange. Beardell FV; Varma M; Martinez J Am J Hematol; 1997 Jan; 54(1):68-71. PubMed ID: 8980263 [TBL] [Abstract][Full Text] [Related]
52. Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency. Wu X; Miao HL; Zhu TN; Feng J; Zhang L; Mao YY; Zhou DB; Cao XX; Li J Amyloid; 2019 Dec; 26(4):255-256. PubMed ID: 31526149 [No Abstract] [Full Text] [Related]
53. Factor X deficiency. Uprichard J; Perry DJ Blood Rev; 2002 Jun; 16(2):97-110. PubMed ID: 12127953 [TBL] [Abstract][Full Text] [Related]
54. Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency. Zimowski KL; McGuinn CE; Abajas YL; Schultz CL; Kaicker S; Batsuli G J Thromb Haemost; 2020 Oct; 18(10):2551-2556. PubMed ID: 32613702 [TBL] [Abstract][Full Text] [Related]
55. [Systemic light chain amyloidosis with acquired factor X deficiency: a case report]. Li L; Zhou F; Hou J Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):506. PubMed ID: 22967401 [No Abstract] [Full Text] [Related]
56. The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade. Ding Q; Shen Y; Yang L; Wang X; Rezaie AR Thromb Haemost; 2013 Jul; 110(1):53-61. PubMed ID: 23677006 [TBL] [Abstract][Full Text] [Related]
57. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions. Muczynski V; Aymé G; Regnault V; Vasse M; Borgel D; Legendre P; Bazaa A; Harel A; Loubière C; Lenting PJ; Denis CV; Christophe OD Blood; 2017 Apr; 129(17):2443-2454. PubMed ID: 28213380 [TBL] [Abstract][Full Text] [Related]
58. Syndrome of acquired factor X deficiency and systemic amyloidosis; in vivo studies of the metabolic fate of factor X. Furie B; Greene E; Furie BC N Engl J Med; 1977 Jul; 297(2):81-5. PubMed ID: 865580 [TBL] [Abstract][Full Text] [Related]
59. A Compound Heterozygosis of Two Novel Mutations Causes Factor X Deficiency in a Chinese Pedigree. Lu S; Lin W; Ji H; Su M; Zhao X; Wang C Acta Haematol; 2021; 144(2):176-181. PubMed ID: 32599596 [TBL] [Abstract][Full Text] [Related]